Cohort (LON:CHRT)

QUOTE AND NEWS
New York Times  Mar 18  Comment 
The Arab cohort, which calls itself the Joint List, received 13 seats in Israel’s next Parliament. But as the euphoria in Arab towns fades, it remains far from clear what influence it will actually have.
Financial Times  Mar 16  Comment 
Opaque rules explained by an older member of generational cohort
TechCrunch  Mar 14  Comment 
 You’re only as strong as your weakest link, and that’s the Internet’s biggest problem today. For more than two decades the very backbone of theInternet — the network — has subsisted in the shadows, pinned beneath the weight of a...
Clusterstock  Mar 6  Comment 
The really fantastic February jobs report shows a hint of wage growth in the economy — but only a hint.  Wages grew at a rate of 2% annually, versus an expectation of 2.2%. That's just barely outpacing inflation, and is a deceleration from...
MedPage Today  Mar 2  Comment 
(MedPage Today) -- Systolic pressure of 128 mmHg or less on antihypertensives questioned in cohort study.
TechCrunch  Feb 24  Comment 
 Drone tech is exciting and full of potential, but few companies are focusing on tech that provides benefits drone users can enjoy now, without spending a fortune or managing an architectural firm or large-scale agricultural concern. Perceptiv...
New York Times  Feb 10  Comment 
A small but growing cohort of people is dedicated to making chocolate at home, a pursuit rooted in the proliferation of American-style, bean-to-bar chocolate.
TechCrunch  Feb 10  Comment 
 Non-profit startups have come into focus at Y Combinator in the last couple of years. And in an extension of that, the incubator is also backing companies that offer services to the wider non-profit sector. Giveffect, part of its current...
Benzinga  Feb 9  Comment 
Shares of Regulus Therapeutics Inc (NASDAQ: RGLS) fell sharply at Monday’s open following the release of the company’s latest top-line HCV RG-101 clinical study. The company noted that an additional year of follow-up has been added to the...
Benzinga  Feb 9  Comment 
Regulus Therapeutics Inc.(NASDAQ: RGLS) shares dropped 12.57% to $14.74 in pre-market trading after the company reported top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study...





 


References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki